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Compound Heterozygosity for a Recurrent 16.5-kb Alu-Mediated Deletion
Mutation and Single-Base-Pair Substitutions in the ABCC6 Gene Results in
Pseudoxanthoma Elasticum
Franziska Ringpfeil,* Aoi Nakano,* Jouni Uitto, and Leena Pulkkinen
Departments of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Pharmacology, Jefferson Medical College, and
Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia
Pseudoxanthoma elasticum (PXE) is a systemic heritable disorder affecting the elastic structures in the skin, eyes,
and cardiovascular system, with considerable morbidity and mortality. Recently, mutations in the ABCC6 gene
(also referred to as “MRP6” or “eMOAT”) encoding multidrug-resistance protein 6 (MRP6), a putative trans-
membrane ABC transporter protein of unknown function, have been disclosed. Most of the genetic lesions delineated
thus far consist of single-base-pair substitutions resulting in nonsense, missense, or splice-site mutations. In this
study, we examined four multiplex families with PXE inherited in an autosomal recessive pattern. In each family,
the proband was a compound heterozygote for a single-base-pair–substitution mutation and a novel, ∼16.5-kb
deletion mutation spanning the site of the single-base-pair substitution in trans. The deletion mutation was shown
to extend from intron 22 to intron 29, resulting in out-of-frame deletion of 1,213 nucleotides from the corresponding
mRNA and causing elimination of 505 amino acids from the MRP6 polypeptide. The deletion breakpoints were
precisely the same in all four families, which were of different ethnic backgrounds, and haplotype analysis by 13
microsatellite markers suggested that the deletion had occurred independently. Deletion breakpoints within introns
22 and 29 were embedded within AluSx repeat sequences, specifically in a 16-bp segment of DNA, suggesting Alu-
mediated homologous recombination as a mechanism.
Introduction
Pseudoxanthoma elasticum (PXE [MIM 177850 and
MIM 264800]), a systemic heritable connective-tissuedis-
order, affects the elastic structures primarily in the skin,
eyes, and cardiovascular system (McKusick 1972; Neld-
ner 1988). The characteristic skin findings consist of yel-
lowish papules that tend to coalesce into larger plaques
of inelastic skin, with primary predilection in the flexural
areas, such as the neck, antecubital fossae, and the groin.
Histopathology of biopsies from the clinically affected
skin shows accumulation of morphologically altered, of-
ten fragmented-appearing, “elastotic” material primarily
in themid dermis (Uitto et al. 1983). Examination of these
biopsies by special stains (e.g., von Kossa) reveals that the
elastic structures are calcified. In addition, a number of
proteins, including osteonectin, fibronectin, and vitronec-
tin, as well as various proteoglycans, have been shown to
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accumulate in the lesional areas of skin, in association
with the elastic fibers (Martinez-Hernandez and Huffer
1974; Baccarani-Contri et al. 1996). Thus, PXE has been
traditionally considered as a prototype of heritable con-
nective-tissue diseases with primary involvement of elastic
fibers (McKusick 1972).
PXEwas originally described as a distinct entity, apart
from xanthomas, 1100 years ago (Darier 1896), but its
molecular basis had remained unresolved. Initially, sev-
eral candidate genes, including elastin and elastin-as-
sociated proteins on chromosomes 5, 7, and 15, were
excluded by genetic linkage analysis (Christiano et al.
1992). More recently, genetic linkage to chromosomal
region 16p13.1, utilizing positional cloning approaches,
was reported (Struk et al. 1997; van Soest et al. 1997),
and, subsequently, the interval containing the PXE locus
was narrowed to ∼500 kb (Le Saux et al. 1999; Cai et
al. 2000). Examination of the sequence covering the
critical interval revealed the presence of four candidate
genes, and, subsequently, we and others disclosed path-
ogenetic mutations in the ABCC6 gene (also referred
to as “MRP6” [multidrug-resistance protein 6] or
“eMOAT”) in a limited number of families with PXE
(Bergen et al. 2000; Germain et al. 2000; Le Saux et al.
2000; Ringpfeil et al. 2000; Struk et al. 2000). The
majority of the genetic lesions disclosed thus far consist
of single-base-pair substitutions, resulting in missense,
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Table 1
Features of Families with PXE That Have the 16.5-kb Deletion Mutation in ABCC6
PROBAND
(ETHNICITY)
AGE
(years)
NO. OF
AFFECTED
FAMILY
MEMBERS
COMPLEMENTARY
MUTATION PHENOTYPEa
When
Studied
At Disease
Onset
1 (German) 61 9 2 R1164X Skin—cobblestoning on neck, antecubital fossae, and wrists,
sagging skin in axillae and bilateral groin; eyes—angioid
streaks, central vision loss; CVS—claudication, ischemic at-
tack; other—ovarian cancer
2 (British) 60 Unknown 3 R1164X Skin—moderate to severe involvement; eyes—loss of vision
3 (British) 41 Unknown 3 R1141X Skin—cobblestoning on neck, axillae, and bilateral groin; eyes—
angioid streaks; CVS—coronary artery disease, GI bleeding
4 (Greek) 60 51 2 37361GrA Skin—cobblestoning in axillae, bilateral groin, and antecubital
fossae; eyes—angioid streaks, central vision loss, macular de-
generation; CVS—angina, abdominal pain, loss of peripheral
pulses; other—depression, chronic fatigue syndrome
a CVS p cardiovascular system; GI p gastrointestinal.
nonsense, or splicing mutations in the ABCC6 gene. In
this study, we have delineated a 16.5-kb, apparently
Alu-mediated deletion mutation, which is detected in
four multiplex families with PXE that are of different
ethnic backgrounds.
Material and Methods
PCR Amplification of ABCC6 Sequences
Total genomic DNA, obtained from members of four
multiplex families with PXE (table 1), was used as a
template for PCR amplification of individual exons of
ABCC6,with TaqDNA polymerase with Q-buffer (Qia-
gen) being used according to the manufacturer’s rec-
ommendations. The primers were placed on flanking in-
tronic sequences, 32 nucleotides away from the
intron-exon borders. The PCR conditions were as fol-
lows: 95C for 3 min; followed by 38 cycles of 95C for
15 s, annealing temperature of the primers (55C–60C)
for 30 s, and 72C for 45 s; and 72C for 5 min. The
sequence information (introns plus exons) of theABCC6
gene was obtained from bacterial artificial chromosome
(BAC) clone A-962B4 (GenBank accession number
U91318), and the intron-exon borders were deduced by
comparison with the published cDNA sequence (Kool
et al. 1999; GenBank accession number AF076622). The
PCR products were examined on 2% agarose gels.
Mutation Detection by Conformation-Sensitive Gel
Electrophoresis (CSGE) and Nucleotide Sequencing
The PCR products corresponding to the ABCC6 ex-
ons were first subjected to heteroduplex analysis by
CSGE on 6%–12% bis-acrylamide gels (Ganguly et al.
1993; Ko¨rkko¨ et al. 1998). In order to detect homo-
zygous mutations, the PCR products from the affected
family members were mixed with an equal amount of
the corresponding PCR product from an unrelated, clin-
ically normal control individual (Christiano et al. 1994).
If CSGE revealed heteroduplexes, the corresponding
PCR products were subjected to direct automated se-
quencing (ABI 377 sequencing system; PE Biosystems).
Verification of Mutations
Nucleotide changes that were potentially pathogenetic
mutations were documented as segregating either with
the disease or with obligate heterozygote carriers, by
restriction-enzyme digestions, if the sequence variant al-
tered a restriction site, and their absence was verified in
50 unaffected, unrelated healthy control individuals. The
digestion products of the restriction-enzyme analysis
were examined on either 2%–4% agarose gels or 6%
polyacrylamide gels (6% TBE Gels; Novex). Alterna-
tively, the corresponding amplicons were examined by
CSGE analysis and/or by direct nucleotide sequencing.
Haplotype Analysis
Microsatellite markers spanning ∼9 cM on chromo-
some 16p13.1, indicated in figure 1 and in table 2 (Ge-
nome Database; also see Cai et al. 2000), were used for
haplotype analysis by PCR amplification. The PCR prod-
ucts were end-labeled with g-[32P]dATP and were ex-
amined on a 6% polyacrylamide sequencing gel (Se-
quaGel; National Diagnostics). In particular, micro-
satellite marker D16B9622, residing ∼0.7 kb downstream
from the translation termination codon within the
ABCC6 gene, was used (Cai et al. 2000).
Characterization of the Deletion Mutation
In order to find the putative deletion, a series of South-
ern blot analyses were performed. For this purpose, 7 mg
of genomic DNA from each of the affected individuals
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Figure 1 Pedigree of family 1 with PXE. The proband (II-5 [arrow]) and her older brother (II-2) were clinically affected. Haplotype
analysis with 12 microsatellite markers (left side) spanning ∼9 cM of 16p13.1 allowed assignment of phase of a deletion mutation (D) and a
nonsense mutation (R1164X), as indicated at the bottom of the haplotypes.
and each normal control was digested with different re-
striction enzymes, including SpeI and HindIII. The diges-
tion products were separated on 0.8% agarose gels and
were transferred to nylon membranes (Hybond N;
Amersham). The membranes were hybridized with
cDNA, and genomic probes were labeled with a[32-
P]dCTP, by use of a Prime-It RmT Random Primer la-
beling kit (Stratagene). The restriction-enzyme patterns
were compared with those obtained from BAC clone A-
962B4 containing the ABCC6 gene. If an altered band
was observed, the corresponding region was carefully
studied by hybridizations with additional cDNA or ge-
nomic probes, to refine the location of the breakpoints.
PCR Detection of the Deletion
After the exact positions of the breakpoints had been
confirmed by PCR with a series of primer pairs within
introns 22 and 29 (see the Results section), the following
primers were designed for diagnostic detection of the
deletion mutation in PXE patients: primer 1, 5′-GGA
ATA CTC AAG GCG AAT GG-3′; primer 2, 5′-TCT
TGA AGC AGC AGT GAG TC-3′; and primer 3, 5′-
TTG AGC AGG CTG ACT GTA GG-3′. These three
primers were used in a single PCR reaction, with stan-
dard conditions being used for amplification. In the case
of normal sequence, a 552-bp PCR product is generated
by primers 2 and 3, whereas in the case of the deletion
mutation primers 1 and 3 result in a 652-bp product.
The annealing temperature for these primers was 57C.
RT-PCR Amplification of ABCC6 mRNA
Total RNA was extracted, by use of standard proce-
dures, from dermal fibroblast cultures established either
from a carrier of the deletion mutation (see the Results
section) or from unrelated controls. cDNA was synthe-
sized (Access RT-PCR system; Promega), and PCR am-
plification of theABCC6 cDNAwas performed under the
conditions described above for genomic DNA amplifi-
cation. The primers revealing the deletionwere as follows:
forward, 5′-GTG AAG GCC ACA GTG CAC C-3′; and
reverse, 5′-TCA GAC CAG GCC TGA CTC C-3′. The
annealing temperature for these primers was 60C.
Clinical Assessment of Families with PXE
Members of families 1, 3, and 4 were personally ex-
amined at least by one of the authors; information on
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Table 2
Haplotypes of Affected Individuals in Four Unrelated Families with
PXE
MARKERa
HAPLOTYPE FORb
del/R1164X
del/R1141X;
Family 3
del/37361GrA;
Family 4Family 1 Family 2
D16S3114 4 4 10 5 9 6 9 4
D16S500 6 3 4 10 4 8 6 10
D16S2619 2 1 3 2 2 3 2 2
D16S3079 2 3 2 3 1 9 8 7
D16S3060 4 2 8 2 7 4 5 8
D16S405 8 3 4 3 4 8 3 4
D16B9622 2 2 2 2 1 2 3 1
D16S764 4 2 3 2 2 2 3 2
D16S79 8 0 3 3 3 3 3 2
D16S3103 7 1 3 1 9 3 7 4
D16S3017 3 2 4 1 5 4 2 4
D16S499 1 5 5 1 8 7 5 8
D16S3036 8 8 7 7 8 11 4 6
a The distances between the listed markers are as follows: telomere,
D16S3114 (1.9 cM)D16S500 (0.5 cM)D16S2619 (0.7 cM)D16S3079
(0.5 cM) D16S3060 (22 kb) D16S405 (430 kb) D16B9622 (0.7 kb)
ABCC6 (317 kb) D16S764 (8 kb) D16S79 (1.5 cM) D16S3103 (0.4
cM) D16S3017 (0.9 cM) D16S499 (1.5 cM) D16S3036, centromere.
The markers flanking the ABCC6 locus are underlined.
b In each column, the numerals to the left denote the alleles harboring
the deletion mutation, whereas those to the right denote the comple-
mentary alleles that contain a single-base-pair substitution. The shared
haplotype in alleles containing the R1164X mutation in families 1 and
2 is in boldface italics.
family 2 was provided by Dr. F.Michael Pope (University
Hospital of Wales) (table 1). The diagnosis of PXE was
made on the basis of cutaneous manifestations, together
with ophthalmologic and cardiovascular findings. In the
affected individuals, the diagnosis was confirmed by his-
topathology of the skin, by hematoxylin-eosin, Verhoeff-
van Gieson, and von Kossa stains. Blood samples were
obtained from the family members after informed con-
sent had been given, and DNA was isolated by standard
procedures.
Results
Strategy for Mutation Analysis and Identification of
Single-Base-Pair Substitutions
Families consisting of individuals with definitive di-
agnosis of PXE were subjected to mutation detection in
the ABCC6 gene. Each of the four families reported here
had two or more affected individuals with biopsy-proved
PXE, the family pedigrees being consistent with auto-
somal recessive inheritance. DNA from the affected in-
dividuals in each family, as well as from their clinically
unaffected family members, was subjected to PCR am-
plification of the ABCC6 gene. The PCR products were
then subjected to heteroduplex scanning analysis by
CSGE, and, if evidence for a heteroduplex was noted,
thereby suggesting the presence of a sequence variant,
the corresponding PCR product was subjected to au-
tomated nucleotide sequencing.
Family 1.—The proband, a 61-year-old female (II-5)
with characteristic clinical features of PXE, was first sub-
jected to analysis, together with her mother (I-5) and her
three clinically unaffected children (III-7, III-8, and III-9)
(fig. 1). Initial heteroduplex scanning ofABCC6 byCSGE
suggested the presence of a sequence variant within exon
24. Comparative sequencing of the proband’s PCR prod-
uct revealed an apparently homozygous single-base-pair
substitution, 3490CrT, which resulted in replacement of
a codon for arginine by a stop codon, a mutation des-
ignated “R1164X” (fig. 2A). This mutation, which abol-
ishes an AciI restriction-enzyme site (fig. 2B), was not
present in 50 unrelated control individuals.
CSGE and sequence analysis of other members of this
family indicated that the older, clinically affected brother
(II-2) of the proband similarly appeared homozygous for
the mutation R1164X. However, the proband’s mother
(I-5) was apparently homozygous for the normal se-
quence (fig. 2A); DNA was not available from the pro-
band’s father, who was deceased. The proband’s mater-
nal aunt (I-10) and paternal uncle (I-1) showed the
normal allele only, whereas the proband’s younger
brother (II-7) was clearly heterozygous for the mutation
R1164X. Sequence analysis of the children (generation
III) of the two affected individuals revealed that five of
them were heterozygous for the mutation R1164X,
whereas two of them (III-2 and III-8) were apparently
homozygous for the normal sequence.
Haplotype analysis in this family was first performed
with 12 microsatellite markers flanking the ABCC6 lo-
cus on chromosome 16p13.1 (fig. 1). This analysis
clearly indicated that the two affected individuals had
inherited one allele from their mother (I-5); the other
allele was presumably of paternal origin (i.e., from in-
dividual I-4). The inheritance of the latter allele con-
ferred heterozygous carrier status of the mutation
R1164X to individuals II-7, III-1, III-4, III-5, III-7, and
III-9 (fig. 1). At the same time, inheritance of the ma-
ternally derived allele from both affected individuals (II-
2 and II-5) to their respective offspring (III-2 and III-8)
resulted in apparent homozygosity for the normal allele.
Collectively, these findings suggest that the proband (II-
5) and her clinically affected older brother (II-2) had
inherited from their father a nonsense mutationR1164X
in exon 24 of the ABCC6 gene, and they had inherited
from their mother a deletion mutation spanning exon
24 of the gene, thus reducing the paternal nonsense mu-
tation to hemizygosity.
Family 2.—The proband was a 60-year-old male with
characteristic clinical features of PXE, including loss of
vision and extensive cutaneous involvement. His older
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Figure 2 Identification of a nonsense mutation inABCC6 in fam-
ily 1 with PXE. A, Results of automated sequencing of the proband’s
PCR product, which revealed an apparently homozygous single-base-
pair substitution, 3490CrT (bottom), in comparison with her mother’s
sequence (top), which showed an apparently homozygous normal se-
quence, 3490C. Sequencing of PCR products of III-7 and III-9 (see fig.
1) showed heterozygous 3490C/T (not shown). The CrT transition
changed the codon for Arg (CGA) to a stop codon (TGA). B, The CrT
substitution abolished an AciI restriction site. Digestion of the 327-bp
PCR product (uncut [lane U] resulted, in the case of the normal allele,
in 239- and 88-bp fragments. Digestions with AciI confirmed that the
proband, II-5, is homozygous for the mutant allele, that her mother, I-
5, is homozygous for the wild-type allele, and that two of the proband’s
children, III-7 and III-9, are heterozygous carriers, whereas another son,
III-8, is apparently homozygous for the normal sequence.
brother was similarly affected. The proband had three
children, and the oldest one, a 39-year-old female, was
not affected. The proband’s second child, a son, was
reported to have clinical findings consistent with PXE,
but he was not available for examination. The youngest
child, also a son, was subjected to clinical examination
at the age of 14 years and was reported to have signs
of PXE, but the diagnosis was not confirmed by skin
biopsy. Initial mutation detection by PCR amplification
of ABCC6, followed by CSGE and nucleotide sequenc-
ing, demonstrated the presence of an apparently ho-
mozygous R1164X mutation in both the proband and
his older brother. This mutation is identical to that in
family 1. Restriction-enzyme digestion with AciI re-
vealed that, of the proband’s three children, the daughter
and the younger son showed evidence for the wild-type
allele only, while the middle child was clearly hetero-
zygous for the R1164X mutation. The two children of
the proband’s daughter, who were examined at the ages
of 12 and 10 years, respectively, were clinically normal
and did not show evidence for the R1164X mutation.
If the proband were truly homozygous for the R1164X
mutation, his children would be expected to be hetero-
zygous carriers of this mutation. Since this mutation was
detected in only one of his three children, it was pos-
tulated that the proband may harbor a deletionmutation
in his other ABCC6 allele
Families 3 and 4.—We have previously described two
families with PXE for which haplotype analysis suggested
a deletion mutation in one of the ABCC6 alleles, while
point mutations were segregating in the other allele
(Ringpfeil et al. 2000). In these families, designated here
as “family 3” (family 3 in Ringpfeil et al. 2000) and
“family 4” (family 4 in Ringpfeil et al. 2000), a nonsense
mutation (R1141X) and a splicing mutation (3736
1GrA) are located in exon 24 and in the 3′ acceptor splice
site of intron 26, respectively. Haplotype analysis suggests
that the putative deletion mutation in both families af-
fected the regions spanning exons 24 and 27, respectively,
reducing the single-base-pair–substitution mutations to
hemizygosity.
Characterization of the Deletion Mutation
In order to delineate the extent of the putative deletion
mutation in family 1, microsatellite markers flanking
ABCC6 and intragenic polymorphisms were utilized (see
table 2). First, D16B9622, which resides ∼0.7 kb down-
stream from the translation termination codon, indicated
that individuals who carry the putative deletion mutation
are distinctly heterozygous for the maternal and paternal
alleles (table 2). This finding suggests that the deletion,
which clearly affects exon 24, does not extend beyond
the 3′ end of the gene. Second, examination of an intra-
genic polymorphism (2490CrT) in exon 19 revealed het-
erozygosity in the proband’s DNA, suggesting that the
deletion breakpoints reside between exon 19 and the
marker D16B9622 at the 3′ end of the gene.
To pinpoint the location of the breakpoints resulting
in the deletion mutation, a series of Southern blot anal-
yses were performed. First, hybridization of HindIII re-
striction-enzyme digests with a cDNA probe spanning
exons 27–31 revealed two bands, 11.9 and 3.7 kb in
size, in normal control individuals, whereas parallel di-
gestions and hybridizations with DNA from the pro-
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Figure 3 Characterization of the 16.5-kb deletion mutation in ABCC6 in PXE. A, Schematic representation of the 3′ end of ABCC6,
including exons 22–31. Positions of HindIII restriction enzyme sites (H) are indicated. Note that the deletion mutation extends from intron 22
to intron 29. The positions of the three primers used for PCR detection of the deletion mutation are indicated (circled numbers) B, Southern
analysis of HindIII digests of DNA isolated from the probands in the four families with PXE (families 1–4 [lanes 1–4, respectively]) and from
four healthy unrelated controls (lanes 5–8). The hybridization was performed with a cDNA probe extending from exon 27 to exon 31. Note
the presence of two constant bands, of 11.9 and 3.7 kb, whereas the individuals with PXE demonstrate an additional, 8.8-kb band. C, PCR
analysis of the deletion mutation in patients with PXE. Three PCR primers at positions shown in panel A and employed in the same PCR
reaction were used for amplification of genomic DNA either from patients with PXE (lanes 1–4) or from unrelated healthy controls (lanes 5–8).
In control individuals, amplification with primers 2 and 3 results in a 552-bp band (wt), whereas, in case of the heterozygous deletion mutation,
primers 1 and 3 result in an additional band, of 652 bp (del).
bands in families 1–4 revealed an additional band, 8.8
kb in size (fig. 3B). Hybridizations of the SpeI digests
with the cDNA probe corresponding to exons 27–31
further suggested that the 3′ breakpoint resides within
intron 29. Similar hybridizations of SpeI restriction-en-
zyme digests, with a cDNA spanning exons 17–26, re-
vealed the presence of several constant bands both in
the controls and in the affected individuals (not shown).
However, an additional band, of ∼11 kb, was noted in
the four probands, suggesting that the deletion is iden-
tical in all four families. The 11-kb band was also seen
when the SpeI digests were probed with a cDNA cor-
responding to exons 22 and 23, localizing the 5′ break-
point to this general region. Finally, hybridization of
HindIII digests with the latter cDNA probe refined the
location of the 5′ breakpoint as residing between a
HindIII site within intron 22 and the beginning of exon
23. Collectively, these results suggest that the probands
in all four families harbor a deletion mutation in one of
their alleles, most likely involving breakpoints within
introns 22 and 29.
In order to identify the precise breakpoint sequences,
a series of primer pairs corresponding to sequences of
intron 22 and of intron 29 were synthesized and were
used for PCR amplification of genomic DNA both from
controls and the probands in families 1–4. Sequencing
of the PCR products resulted in identification of the
breakpoints within intron 22 (nucleotide 47322) and
within intron 29 (nucleotide 30869). This deletion was
calculated to be 16.5 kb and was predicted to delete
exons 23–29 from the gene (fig. 3A). Identification of
these breakpoints allowed us to develop an amplification
system consisting of three primers, as shown in figure
3A, with two of the primers (i.e., primers 1 and 3) being
placed just outside the breakpoints, whereas the third
primer (i.e., primer 2) was localized inside the deletion.
In the case of normal sequence a 552-bp PCR product
is generated by primers 2 and 3, whereas in the case of
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the deletion a 652-bp PCR product is observed with
primers 1 and 3 (fig. 3C). This PCR assay provides a
rapid means to identify the presence of this 16.5-kb de-
letion in families with PXE. Consequently, the deletion
breakpoints, as determined by sequencing of the PCR
products generated by primers 1 and 3, were found to
be identical in all four families reported here. Exami-
nation of a cohort of 26 additional families with PXE
did not reveal the presence of this deletion. Thus, the
frequency of this deletion mutation in the patient pop-
ulation studied is 1/15. The incidence of PXE has been
reported to be 1:160,000 (Sherer et al. 1999). On the
basis of this estimate, the frequency of carriers of PXE
is calculated to be 1/200, and the frequency of the de-
letion mutation delineated in this study is 1/3,000. Fi-
nally, extensive Southern analyses did not reveal evi-
dence for other large deletions in the DNA of other
patients with PXE (data not shown).
Consequences of the Deletion at the mRNA Level
To verify the consequences that the genomic deletion
has at the mRNA level, reverse transcriptase–PCR using
skin fibroblast RNA as template was performed with
primers placed on exons 22 and 31 of the corresponding
mRNA. Sequencing of the PCR product clearly indicated
the absence of 1,213 nucleotides corresponding to exons
23–29 (nucleotides 2997–4208; GenBank accession num-
ber AF168791) (fig. 4A). This mutation predicts deletion
of 405 amino acids, encoded by exons 23–29, from the
MRP6 protein, followed by a 60-amino-acid missense se-
quence and a premature termination codon (PTC) for
translation within exon 30. This results in elimination of
most of the third transmembrane spanning domain
(TMSD3) sequence, as well as of the entire second nu-
cleotide-binding fold (NBF2) sequence (fig. 4A). Elimi-
nation of TMSD3 and NBF2 sequences predicts synthesis
of a nonfunctional polypeptide.
Haplotype Analysis of Families 1–4
The recurrent 16.5-kb genomic deletion in one allele
of patients with PXE could reflect the presence of a foun-
der effect, or alternatively, it could be a recurring event.
To examine these two possibilities, a panel of 13 mi-
crosatellite markers flanking the ABCC6 locus was util-
ized for haplotype analysis. These microsatellites span
∼9 cM of DNA, and their distances are specified in the
legend to table 2. Note that the distance between the
two markers closest to the ABCC6 locus is 390 kb, in-
dicating that the likelihood of recombination is signifi-
cantly less than 1%. Examination of the haplotype of
the alleles, specifically those of the two closest markers
(D16B9622 and D16S764) containing the deletion mu-
tation indicated that each proband had a distinct hap-
lotype (table 2). Thus, there is no evidence of common
ancestry, and the deletion mutation appears to have
arisen independently in these four families.
The deletion mutation in each of these four families is
associated with single-base-pair substitutions, two of
them being the same one—R1164X in families 1 and 2.
Haplotype analysis of the allele containing this nonsense
mutation revealed a similar haplotype for five markers
directly flanking the PXE-gene locus, between D16S3079
and D16S764, spanning ∼1.5 cM (table 2). Thus, a foun-
der effect for the R1164X mutation cannot be excluded
with certainty, despite the apparently diverse ethnic back-
grounds of these two families (table 1).
Discussion
The ABCC6 gene encoding an ABC transporter protein,
MRP6, has recently been shown to harbor mutations
underlying PXE, most of the genetic lesions being single-
base-pair substitutions resulting in nonsense, missense,
or splice-site mutations (Bergen et al. 2000; Germain et
al. 2000; Le Saux et al. 2000; Ringpfeil et al. 2000; Struk
et al. 2000). The gene consists of 31 distinct exons span-
ning ∼73 kb of DNA, and the corresponding mRNA,
∼6 kb in size with an open reading frame of 4.5 kb,
encodes a polypeptide of 1,503 amino acids with a cal-
culated molecular mass of 165 kD (Belinsky and Kruh
1999; Kool et al. 1999). MRP6 has a high degree of
identity (∼62%) with MRP1, the prototype within the
MRP family of proteins (Belinsky and Kruh 1999). The
function of MRP6 is currently unknown, but, in analogy
to other members of the MRP family of transmembrane
transporter proteins, it has been proposed to serve as an
efflux pump eliminating metabolic compounds from the
intracellular milieu.
The utility of strategies to identify PXE mutations in
ABCC6 has been demonstrated in this study in four
multiplex families with PXE. In each family, the pro-
band was initially shown to be apparently homozygous
for a nucleotide substitution, resulting in either a non-
sense mutation (R1164X, R1164X, and R1141X in
families 1, 2, and 3, respectively) or a splice-site mu-
tation (37361GrA in family 4). These nucleotide sub-
stitutions were not present in 50 unrelated control in-
dividuals, excluding these substitutions from being
polymorphisms. Interestingly, however, some children
of the affected individuals in families 1, 2, and 4 showed
the presence of the normal sequence only. It was con-
cluded, therefore, that the affected individuals were
compound heterozygotes for a single-base-pair–sub-
stitution mutation and a deletion mutation in ABCC6,
and the presence of the deletion mutation reduces the
single-base-pair–substitution mutation to hemizygosity.
The recurrent deletion mutation, delineated in this
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Figure 4 Schematic structure of the MRP6 protein, consisting of three TMSDs (TMSD1–TMSD3) and two NBFs (NBF1 and NBF2) (A)
and the repetitive sequences surrounding the breakpoints in ABCC6 (B). A, 16.5-kb genomic deletion, resulting in out-of-frame elimination of
1,213 bp from the ABCC6mRNA corresponding to exons 23–29. At the protein level, deletion of these exons is predicted to result in elimination
of most of the sequences within TMSD3 as well as of the entire NBF2. A downstream PTC for translation, resulting in truncation of the
polypeptide at amino acid position 1463, is indicated by a white arrow. B, Abundance of repetitive sequences within introns 22 and 29. Alu
and other interspersed repetitive elements are denoted by black arrows along the intronic sequences, and the types of these elements are identified
the arrows. The white arrowheads denote the positions of simple repeats, and the asterisks denote the positions of the AluSx repeats containing
the deletion breakpoints (top). Note the overall sequence homology in AluSx repeats, including a 16-bp sequence containing the deletion
breakpoints (yellow), within introns 22 and 29 (bottom). The boldface type represents continuation of the DNA strands after the deletion event.
study of four unrelated families, has been shown to span
∼16.5 kb of the ABCC6 gene, from intron 22 to intron
29. This deletion is predicted to result in an MRP6
polypeptide, which is shortened by 505 amino acids,
the last 60 amino acids being missense sequences. This
polypeptide, which is devoid of intact TMSD3 and
NBF2, is nonfunctional. In all four families examined,
the breakpoints within intron 22 and intron 29 have
been shown by direct nucleotide sequencing to be pre-
cisely the same.
Analysis of the sequences spanning the deletion
breakpoints to detect possible repetitive elements was
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performed by the RepeatMasker Documentation pro-
gram and suggested that the deletion mechanism is Alu
mediated. Specifically, a recombination event between
two highly homologous AluSx repeats within introns
22 and 29 is likely responsible for the occurrence of the
deletion, and the site of the crossover event lies within
a 16-bp sequence (aacatggtgaaacccc) (fig. 4B). Similar
analysis of the entire ABCC6 gene revealed a high con-
tent of repetitive elements, which account for ∼60% of
all intronic sequences. Specifically, the introns 22 and
29 harbor 14 repetitive sequence elements each, ac-
counting for 67% and 75% of the intronic sequences,
respectively. These repetitive elements are depicted in
figure 4B, and include, in addition to Alu and other
interspersed repetitive elements, three simple repeats,
(TTTA)n, (TTTG)n, and (CCCCCA)n. Alu-mediated re-
arrangements have been shown to be a cause of a num-
ber of inherited diseases, such as Fanconi anemia (Mor-
gan et al. 1999), familial hypercholesterolemia (Lehr-
man et al. 1987), and hereditary angioedema (Stoppa-
Lyonnet et al. 1990), as well as a cause of predisposition
to colon cancer (Nystro¨m-Lahti et al. 1995) and breast
cancer (Puget et al. 1999). In addition, acute myeloid
leukemia can be caused by Alu-mediated recombina-
tional events in somatic tissue (Strout et al. 1998). It is
conceivable that, because of the abundance of repetitive
sequence elements, the ABCC6 gene is prone to Alu-
mediated rearrangements, such as deletions, insertions,
duplications, or inversions. These possibilities should
be taken into account when one is planning strategies
for the search of the gene defects in PXE.
The MRP6 protein consists of three TMSDs
(TMSD1–TMSD3), and it has two intracellular NBFs,
both critical for the function of the protein as a trans-
membrane transporter (Belinsky and Kruh 1999) (fig.
4A). Exon 24 encodes a segment of MRP6 residing
within TMSD3, and the mutations R1141X and
R1164X are predicted to result in the synthesis of a
truncated polypeptide entirely devoid of NBF2 (fig. 4A).
In addition, these PTC mutations could result in re-
duction of the MRP6-transcript levels, through non-
sense mutation–mediated mRNA decay (Hentze and
Kulozik 1999). Similarly, the splicing mutation
37361GrA (Ringpfeil et al. 2000) predicts in-frame
splicing of exon 27, resulting in deletion of 49 amino
acids within the NBF2 domain. As a consequence, no
functional MRP6 is predicted to be synthesized, which
results in the PXE phenotype.
The specific biological function of MRP6, which is
primarily expressed in the liver and the kidneys, is cur-
rently unknown (Belinsky and Kruh 1999; Kool et al.
1999). However, MRP1, the best-characterized protein
within the MRP family, functions as an efflux pump for
amphipathic anion conjugates. One could speculate that
the mechanisms involved in the development of PXE
could be analogous to those in Dubin-Johnson syn-
drome, an autosomal recessive disorder characterized
by conjugated hyperbilirubinemia with otherwise nor-
mal liver function (MIM 237500). In this condition,
MRP2, another ABC transporter within theMRP family
of proteins, is inactivated by mutations affecting the
NBFs (Wada et al. 1998; Toh et al. 1999). As a result
of deficiency in MRP2, up-regulation ofMRP3 has been
observed (Ko¨nig et al. 1999). Since MRP2 is located
apically whereas MRP3 resides basolaterally (Paulusma
et al. 1996; Ko¨nig et al. 1999), the metabolites are not
removed from hepatocytes to the bile; instead, the com-
pounds are conjugated in the liver and transported back
to the systemic circulation. Thus, MRP6 function may
relate to cellular detoxification, and, when genetically
altered to be nonfunctional, it may cause accumulation
of yet-unidentified compounds that potentially lead to
progressive calcification of elastic structures in the target
tissues. If this hypothesis is proved to be correct, then
PXE could be considered to be a metabolic disease,
rather than a primary heritable connective-tissue dis-
order (Uitto et al. 2001).
PXE demonstrates considerable clinical and genetic
heterogeneity (Pope 1975; Neldner 1988). Although
many families with PXE present with autosomal reces-
sive inheritance, an autosomal dominant pattern also
has been reported, and many of the cases appear to be
sporadic. It has been suggested that, in families in which
PXE is autosomal recessive, the heterozygous carriers
may show partial manifestations of the disease (Altman
et al. 1974; Neldner 1988; Bacchelli et al. 1999). How-
ever, clinical identification of the affected individuals
and potential carriers with partial manifestations is
complicated by delayed onset of the clinical findings, as
well as by the fact that cutaneous signs mimicking PXE
are frequently encountered in sun-damaged areas of skin
in older individuals. Furthermore, other diagnostic
manifestations of PXE, such as cardiovascular involve-
ment, are prevalent in the general population, although
usually at a later age (Mendelsohn et al. 1978; Neldner
1988). This diagnostic dilemma in PXE can now be
overcome by delineation of specific mutations in the
ABCC6 gene, which allows both unequivocal identifi-
cation of the affected individuals and DNA-based car-
rier detection in families with a history of PXE.
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